New York Life Investment Management LLC Cuts Holdings in DexCom, Inc. (NASDAQ:DXCM)

New York Life Investment Management LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,606 shares of the medical device company’s stock after selling 600 shares during the quarter. New York Life Investment Management LLC’s holdings in DexCom were worth $4,558,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Blue Whale Capital LLP increased its holdings in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after buying an additional 113,000 shares during the period. Brooktree Capital Management purchased a new position in DexCom in the third quarter worth $683,000. National Pension Service grew its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Intact Investment Management Inc. purchased a new position in DexCom in the third quarter worth $650,000. Finally, Motley Fool Asset Management LLC grew its holdings in DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of several analyst reports. Citigroup lifted their price target on shares of DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company lifted their price target on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, Morgan Stanley lifted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Trading Up 0.6 %

NASDAQ DXCM opened at $88.37 on Friday. The company has a market capitalization of $34.53 billion, a PE ratio of 61.80, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a fifty day moving average of $84.69 and a 200 day moving average of $76.67. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.